MAR 10, 2017 12:14 PM PST

The Best Is Yet To Come for Heart Failure Treatments

WRITTEN BY: Kara Marker

A careful balance must be struck between various pathways in the body, or adverse cardiac events like heart attacks and strokes can occur, and diseases like heart failure can develop. University of Alberta scientists are in the business of studying this balance, and their recent discovery of a new molecule makes balancing ten times easier.

Nearly six million American adults have heart failure. Credit: Everyday Health

When an individual’s heart can no longer pump enough blood to adequately supply the body tissues with oxygenated blood, the condition is called heart failure. Early diagnosis and treatment gives heart failure patients the best chance at a longer, more fulfilling life, but even the most advanced treatments are focused on reducing symptoms and preventing progression, rather than a cure.

The discovery

The University of Alberta discovery is that of a molecule called angiotensin converting enzyme 2 (ACE2) which, as its name suggests, negatively alters a hormone called angiotensin. This hormone is part of a pathway called the renin-angiotensin system (RAS) that is activated during heart failure. So naturally, drugs targeting RAS are used to treat heart failure, and ACE2 could be the next molecule for development.

What does “RAS” have to do with heart failure?

RAS is a master regulator of several physiological activities, mainly keeping the sodium balance, regulating fluid volume, and managing blood pressure. The last activity is especially important for cardiovascular disease, but RAS is also activated in the kidneys and central nervous system. Thus, inhibitors of RAS are also used to treat kidney disease.

Researchers used a novel genetic mapping technology to observe how RAS is involved in both acute and chronic heart failure, including heart transplant patients with heart failure. As a negative regulator of angiotensin, ACE2 can be used to improve all types of heart failure situations.

New heart failure drugs

Based on their research, University of Alberta outlined the steps necessary to create a new drug based on recombinant human ACE2, and it is expected to be on the market within three to five years.

In addition to the new ACE2 drug, the same genetic mapping technology used in this study boosts the potential of individualized medicine for heart failure drugs, providing personalized options to patients on a case-by-case basis.

The recent study was published in Journal of the American College of Cardiology.

Sources: Comprehensive Physiology, American Heart Association, National Heart, Lung, and Blood Institute, University of Alberta Faculty of Medicine & Dentistry

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 18, 2021
Clinical & Molecular DX
"Hey Alexa, Are My Heart Rhythms Normal?"
MAR 18, 2021
"Hey Alexa, Are My Heart Rhythms Normal?"
Smart speakers—devices such as Amazon’s Echo and the Google Home—lend a helping hand around the house, ...
MAR 15, 2021
Cardiology
'Silent' Heart Attacks Linked to Significant Increase in Stroke Risk
MAR 15, 2021
'Silent' Heart Attacks Linked to Significant Increase in Stroke Risk
Silent heart attacks can happen, in which blood flow to the heart is blocked, and heart tissue may be damaged, but they ...
APR 13, 2021
Cardiology
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
APR 13, 2021
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
Quick and reliable diagnostics are the key to controlling many diseases, including cardiovascular disease. Biomarkers ar ...
MAY 19, 2021
Immunology
Intestinal Macrophages Promote Chronic Inflammation in Obesity
MAY 19, 2021
Intestinal Macrophages Promote Chronic Inflammation in Obesity
A research group from Switzerland hypothesized that immune cells in the gut (gastrointestinal tract) must trigger chroni ...
JUN 28, 2021
Cardiology
The Electricity of a Beating Heart is Caught on Graphene Camera
JUN 28, 2021
The Electricity of a Beating Heart is Caught on Graphene Camera
When graphene was first developed, it was hailed as a revolutionary material but its potential uses seemed unclear to ma ...
SEP 16, 2021
Clinical & Molecular DX
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
SEP 16, 2021
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
Forget uncomfortable chest straps or clunky wristbands—thanks to a new innovation in nanotechnology, your t-shirt ...
Loading Comments...